Tuberculosis
Conditions
Interventions
Arm 1 (R35): HR35ZE isoniazid, rifampicin 35 mg/kg, pyrazinamide, ethambutol
Arm 2 (Q): HRZQ isoniazid, rifampicin standard, pyrazinamide, SQ109 300 mg
Arm 3 (R20Q): HR20ZQ isoniazid, rifampicin 20 mg/kg, pyrazinamide, SQ109 300 mg
Arm 4 (R20M): HR20ZM isoniazid, rifampicin 20 mg/kg, pyrazinamide, moxifloxacin 400mg
Control: HRZE isoniazid, rifampicin standard, pyrazinamide, ethambutol
Sponsors
Prof. Karl Walter Jauch, Medical Director, Klinikum of the Universtiy of Munich
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. The patient has given free, signed written or witnessed oral informed consent for study participation prior to all trial-related procedures, including HIV testing. ago. 2. The patient has a diagnosis of pulmonary TB. 3. An adequate sputum bacterial load is confirmed by a Ziehl-Neelsen stained smear in the study laboratory. 4. The patient has a valid rapid test result (GeneXpert MTB/RIF®) from the sputum positive for MTB complex, and indicating susceptibility to Rifampicin. 5. The patient is aged at least 18 years at the day of informed consent. 6. The patient has a body weight of at least 35 kg, but not more than 90 kg. 7. Female patients of childbearing potential must have a negative serum pregnancy test, and consent to practise an effective method of birth control until week 26. 8. Male patients must consent to use an effective contraceptive method, if their sexual partner(s) is/are of childbearing potential, and if they are not surgically sterile. 9. The patient has a firm home address that is readily accessible for visiting and willingness to inform the study team of any change of address during the treatment and follow-up period, or will be compliant to study schedule and follow-up in the discretion of the investigator.
Exclusion criteria
Exclusion criteria: 1. Circumstances that raise doubt about free, uncoerced consent to study participation. 2. Poor General Condition. 3. The patient is pregnant or breast-feeding. 4. The patient has an HIV infection. 5. The patient has a known intolerance to any of the study drugs, or concomitant disorders or conditions for which SQ109, rifampicin, moxifloxacin, or standard TB treatment are contraindicated. 6. The patient has an history or evidence of clinically relevant metabolic, gastrointestinal, neurological, psychiatric or endocrine diseases, malignancy, or any other condition that will influence treatment response, study adherence or survival in the judgement of the investigator. 7. History of previous TB within the last five years. 8. Laboratory: at screening one or more of the following abnormalities were observed for the patient in screening laboratory: AST and/or ALT activity >3x the upper limit of normal, serum total bilirubin level >2.5 times the upper limit of normal, Creatinine clearance (CrCl) level greater than 30 mls/min, Complete blood count with hemoglobin level 0.450 s, AV block with PR interval > 0.20 s, prolongation of the QRS complex over 120 milliseconds, other changes in the ECG that are clinically relevant as per discretion of the investigator. 10. The patient has had treatment with any other investigational drug within 1 month prior to enrolment. 11. Previous anti-TB treatment. 12. QT prolonging medications. 13. CYP 450 inducers/inhibitors: administration within 30 days prior to dosing.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to stable culture conversion to negative in liquid media defined as the time from enrolment to the first of two negative weekly sputum cultures without an intervening positive culture in liquid media. | — |
Countries
South Africa, Tanzania
Contacts
Public ContactAnna-Maria Mekota
Project manager
Outcome results
None listed